drugset
drugset / Trial / NCT04991766

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

NCT04991766 ↗

Phase 1 Completed 16 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study has two parts. It will involve a single dose of 14C radiolabeled LY3484356. This means that a radioactive substance C14 will be incorporated into the study drug, to investigate the study drug and its breakdown products, to find out how much of these pass from blood into urine, feces and expired air. The study will last about 4 weeks. Screening is required within 28 days prior to the start of the study and follow up is required approximately 7 days after discharge.

Timeline

Start
2021-08-13
Primary completion
2022-04-02
Completion
2022-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Imlunestrant Small molecule 100 ug Oral
Subject Imlunestrant Small molecule 400 mg Oral

Indications

No indication recorded.